Funding

[Recherche] Toute l’équipe de la plateforme IMATHERA (IMAgerie préclinique et THErapie par les radiations ionisantes, #BioSanD – UMS #INSERM  58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) du #CGFL est fière d’annoncer sa participation en tant que partenaire à deux projets de recherche préclinique financés par l’ANR :

– Le projet SUPRALABEL, dirigé par @Victor Goncalves (#ICMUB – UMR CNRS 6302) en partenariat avec @Pierre-Simon Bellaye (#CGFL) centré sur l’évaluation d’une stratégie innovante d’imagerie de la fibrose pulmonaire.

– Le projet Nose To brain N2B – Dirigé par @Didier Boquet (#CEA, Saclay) en collaboration avec @Franck Denat (#ICMUB – UMR CNRS 6302) et @Bertrand Collin (#CGFL, #ICMUB – UMR CNRS 6302) centré sur l’évaluation d’une stratégie d’injection intranasale de thérapie ciblant les métastases cérébrales.

[Research] The entire IMATHERA platform team (IMAgerie préclinique et THErapie par les radiations ionisantes, #BioSanD – UMS #INSERM 58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) at the #CGFL is proud to announce its participation as a partner in two preclinical research projects funded by the ANR :

– The SUPRALABEL project, led by @Victor Goncalves (#ICMUB – UMR CNRS 6302) in partnership with @Pierre-Simon Bellaye (#CGFL) focused on the evaluation of an innovative imaging strategy for pulmonary fibrosis.

– The Nose To brain N2B project – led by @Didier Boquet (#CEA, Saclay) in collaboration with @Franck Denat (#ICMUB – UMR CNRS 6302) and @Bertrand Collin (#CGFL, #ICMUB – UMR CNRS 6302) – focused on evaluating an intranasal injection strategy for therapy targeting brain metastases.

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Alexandre DIAS (IMATHERA, CGFL) obtained funding through the young researcher programm of ANR of €324,000 over 3 years (2024-2027). This project entitled “Improved imaging and therapy of HER2-low breast cancer” (EITHER2BC) aims at developing theranostic probes (combining properties for diagnosis and therapy) targeting HER2, in a HER2-low context, could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of these patients. This project will be driven in collaboration with ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the INCA of €130,000 over 3 years (2024-2027) as partner of a global INCA project entitled “Development of bimodal antibodies targeting colorectal and pancreatic tumors for fluorescenceguided surgery application”. This project is led by Dr Catherine Paul (École Pratique des Hautes Études – Université PSL) and in collaboration with the ICMUB (Dr Goze Christine) and Besançon University Hospital (Dr Doussot Alexandre).

​

Probes developed in this prject will be tested for FGS in various preclinical models mimicking human pathology, such as orthotopic models of colon and pancreatic cancers, but also models mimicking the formation of liver metastases or peritoneal carcinomatosis. The expected results of this project are fine visualisation of tumours before surgery (SPECT imaging) and more accurate detection by fluorescence, enabling the extent of resection to be minimised. Finally, it will be possible to detect the absence of recurrence using this compound a few weeks after surgery (SPECT).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Drs Alexandre COCHET and Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the FEDER of 3.6 M€ over 5 years (2023-2028). This project entitled “moleCular radiOtherapy for Metastatic ColorEcTal and Gastric cancErs” (COMETE) aims at developing theranostic probes (for RIT and associated companion diagnostics) in colorectal and gastric cancers that could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of patients.

This project will be driven by Oncodesign Precision Medicine (OPM, Dijon) with a third parter, ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).